AU2019265707B2 - Magnetic liposomes and related treatment and imaging methods - Google Patents

Magnetic liposomes and related treatment and imaging methods Download PDF

Info

Publication number
AU2019265707B2
AU2019265707B2 AU2019265707A AU2019265707A AU2019265707B2 AU 2019265707 B2 AU2019265707 B2 AU 2019265707B2 AU 2019265707 A AU2019265707 A AU 2019265707A AU 2019265707 A AU2019265707 A AU 2019265707A AU 2019265707 B2 AU2019265707 B2 AU 2019265707B2
Authority
AU
Australia
Prior art keywords
rna
liposome
liposomes
cells
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019265707A
Other languages
English (en)
Other versions
AU2019265707A1 (en
Inventor
Jon P. DOBSON
Adam J. GRIPPIN
Duane Mitchell
Adam Monsalve
Elias SAYOUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of AU2019265707A1 publication Critical patent/AU2019265707A1/en
Application granted granted Critical
Publication of AU2019265707B2 publication Critical patent/AU2019265707B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Ceramic Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019265707A 2018-05-08 2019-05-08 Magnetic liposomes and related treatment and imaging methods Active AU2019265707B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668608P 2018-05-08 2018-05-08
US62/668,608 2018-05-08
PCT/US2019/031385 WO2019217593A1 (en) 2018-05-08 2019-05-08 Magnetic liposomes and related treatment and imaging methods

Publications (2)

Publication Number Publication Date
AU2019265707A1 AU2019265707A1 (en) 2020-11-26
AU2019265707B2 true AU2019265707B2 (en) 2025-03-27

Family

ID=66677229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019265707A Active AU2019265707B2 (en) 2018-05-08 2019-05-08 Magnetic liposomes and related treatment and imaging methods

Country Status (6)

Country Link
US (1) US20210077399A1 (https=)
EP (1) EP3790533A1 (https=)
JP (2) JP7525162B2 (https=)
AU (1) AU2019265707B2 (https=)
CA (1) CA3099519A1 (https=)
WO (1) WO2019217593A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020037102A1 (en) 2018-08-15 2020-02-20 University Of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
EP3962521A1 (en) 2019-05-02 2022-03-09 University of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
EP3999034A4 (en) * 2019-07-19 2023-08-23 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticles
EP4099988A4 (en) * 2020-02-05 2024-03-13 University of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
WO2022036231A1 (en) * 2020-08-14 2022-02-17 University Of Florida Research Foundation Biocompatible nanocomposite hydrogel immunotherapy vaccines and methods of use thereof
CN114848840B (zh) * 2022-03-24 2023-08-29 北京福纳康生物技术有限公司 修饰的铁基纳米材料、铁基纳米脂质体及其抗肿瘤的应用
CN119470536B (zh) * 2024-11-03 2025-09-30 中国科学院精密测量科学与技术创新研究院 利用多核磁共振预测氟化脂质纳米颗粒转染效率的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047981A2 (en) * 2005-10-20 2007-04-26 Georgetown University Tumor-targeted nanodelivery systems to improve early mri detection of cancer
WO2011112597A1 (en) * 2010-03-08 2011-09-15 Northeastern University Magnetic nanoplatforms for theranostic and multi-modal imaging applications
US20170367982A1 (en) * 2016-06-24 2017-12-28 Northwestern University High density lipoprotein functionalized magnetic nanostructures

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA195563A (en) 1919-08-08 1919-12-30 Aaron Terry Heating system
US7001614B2 (en) * 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6413544B1 (en) 1996-08-19 2002-07-02 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
NZ592917A (en) * 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
KR20150078952A (ko) * 2013-12-31 2015-07-08 삼성전자주식회사 활성 성분 및 조영제를 포함하는 리포좀 및 그의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047981A2 (en) * 2005-10-20 2007-04-26 Georgetown University Tumor-targeted nanodelivery systems to improve early mri detection of cancer
WO2011112597A1 (en) * 2010-03-08 2011-09-15 Northeastern University Magnetic nanoplatforms for theranostic and multi-modal imaging applications
US20170367982A1 (en) * 2016-06-24 2017-12-28 Northwestern University High density lipoprotein functionalized magnetic nanostructures

Also Published As

Publication number Publication date
CA3099519A1 (en) 2019-11-14
JP2024160224A (ja) 2024-11-13
EP3790533A1 (en) 2021-03-17
WO2019217593A1 (en) 2019-11-14
US20210077399A1 (en) 2021-03-18
JP7525162B2 (ja) 2024-07-30
JP2021523145A (ja) 2021-09-02
AU2019265707A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
AU2019265707B2 (en) Magnetic liposomes and related treatment and imaging methods
EP3668522B1 (en) Efficacious mrna vaccines
Munakata et al. Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice
US12514930B2 (en) Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
US20230226169A1 (en) Multilamellar rna nanoparticle vaccine against sars-cov-2
US20230096704A1 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
JP7783628B2 (ja) 多層ｒｎａナノ粒子
US20230346700A1 (en) Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
JP2025507571A (ja) チェックポイントがんワクチンをコードするｍＲＮＡ及びその使用
US20240238418A1 (en) Car t cell therapy method
US20250231177A1 (en) Method of characterizing tumors
JP2026501441A (ja) 核酸－脂質粒子
CA3166934A1 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
WO2025207807A1 (en) Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer
Grippin Engineering Nanoparticles for Treatment of Glioblastoma
WO2025031498A1 (zh) Toll样受体激动剂及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)